GetTopicDetailResponse(id=32354938ec3, topicName=度伐單抗, introduction=度伐單抗, content=null, image=null, comments=1, allHits=1523, url=https://h5.medsci.cn/topic?id=49387, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=95359, tagList=[TagDto(tagId=95359, tagName=度伐單抗)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2228403, encodeId=3aaf2228403db, content=<a href='/topic/show?id=231c10011915' target=_blank style='color:#2F92EE;'>#順鉑#</a> <a href='/topic/show?id=10dc3890e66' target=_blank style='color:#2F92EE;'>#吉西他濱#</a> <a href='/topic/show?id=32354938ec3' target=_blank style='color:#2F92EE;'>#度伐單抗#</a> <a href='/topic/show?id=22d9119e029a' target=_blank style='color:#2F92EE;'>#膽道癌(BTC)#</a>, objectTitle=UEGJ：吉西他濱、順鉑和度伐單抗免疫化療用于膽道癌患者的療效、安全性和差異結(jié)局, objectType=article, longId=845083, objectId=0790845083ae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240924/1727154795335_8538692.jpg, objectUrl=/article/show_article.do?id=0790845083ae, replyNumber=0, likeNumber=147, createdTime=2024-09-29, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0790845083ae, moduleTitle=UEGJ：吉西他濱、順鉑和度伐單抗免疫化療用于膽道癌患者的療效、安全性和差異結(jié)局, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0790845083ae)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=886691, encodeId=019688669105, content=<a href='/topic/show?id=32354938ec3' target=_blank style='color:#2F92EE;'>#度伐單抗#</a>, objectTitle=2020 ESMO：英飛凡治療III期非小細(xì)胞肺癌迎來重大突破，約50％的患者獲得了長達(dá)四年的生存期, objectType=article, longId=200935, objectId=015b2009357f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/097.jpg, objectUrl=/article/show_article.do?id=015b2009357f, replyNumber=0, likeNumber=0, createdTime=2020-09-19, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015b2009357f, moduleTitle=2020 ESMO：英飛凡治療III期非小細(xì)胞肺癌迎來重大突破，約50％的患者獲得了長達(dá)四年的生存期, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=015b2009357f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
